The next great pharmaceutical multidistrict litigation may have arrived — in the form of thousands of claims against the prescription pain medications Darvon and Darvocet, which the manufacturer recalled under government pressure about two months ago.
Since Dec. 3, seven lawsuits have been filed in federal court alleging that Xanodyne Pharmaceuticals Inc., the manufacturer of Darvocet and Darvon, knew of the risks but failed to warn doctors and the general public that the medications could contribute to heart disease. The suits, some them class actions, were filed on behalf of people who suffered from heart problems or died after taking the drugs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
